Dermata Therapeutics Inc (DRMA)

Apr 16, 2025

Dermata Therapeutics stock hits 52-week low at $0.7 By Investing.com - Investing.com South Africa

Apr 16, 2025

Apr 16, 2025

Dermata Therapeutics stock hits 52-week low at $0.7 - Investing.com Australia

Apr 16, 2025

Apr 15, 2025

Dermata reports early success in acne treatment with XYNGARI By Investing.com - Investing.com South Africa

Apr 15, 2025

Apr 15, 2025

Dermata Therapeutics (DRMA) Reports Promising Phase 3 Trial Resu - GuruFocus

Apr 15, 2025

Apr 15, 2025

Dermata Therapeutics IncAnnounces Topline Results From Phase 3 Trial Of XyngariSEC Filing - marketscreener.com

Apr 15, 2025

Apr 15, 2025

Dermata reports early success in acne treatment with XYNGARI - Investing.com

Apr 15, 2025

Apr 15, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 15, 2025

Apr 15, 2025

First-Ever Weekly Acne Treatment XYNGARI Achieves Major Phase 3 Success - Stock Titan

Apr 15, 2025

Apr 15, 2025

Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Up 307.9% in March - Defense World

Apr 15, 2025

Apr 09, 2025

Dermata Therapeutics stock hits 52-week low at $0.79 By Investing.com - Investing.com Canada

Apr 09, 2025

Apr 09, 2025

Dermata Therapeutics stock hits 52-week low at $0.79 - Investing.com

Apr 09, 2025

Apr 04, 2025

Acne Vulgaris Market to Reach New Heights in Growth by 2034, - openPR.com

Apr 04, 2025

Apr 01, 2025

Dermata Therapeutics stock hits 52-week low at $1 - Investing.com

Apr 01, 2025

Mar 28, 2025

Dermata (DRMA) Initiates Warrant Exercise to Raise $6.2 Million - GuruFocus

Mar 28, 2025

Mar 28, 2025

Biotech Stock Dermata Therapeutics, Inc. (Nasdaq: DRMA) Makes NASDAQ Top Gainer List on Positive Phase 3 Results - Investorideas.com

Mar 28, 2025

Mar 28, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Mar 28, 2025

Mar 28, 2025

Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 28, 2025

Mar 28, 2025

Dermata Therapeutics (NASDAQ:DRMA) Shares Up 5.2% – Here’s What Happened - Defense World

Mar 28, 2025

Mar 27, 2025

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules - Yahoo Finance

Mar 27, 2025

Mar 27, 2025

Dermata Raises Fresh $6.2M Capital: New Funding Fuels Clinical Pipeline Advancement - Stock Titan

Mar 27, 2025

Mar 27, 2025

Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results - Benzinga

Mar 27, 2025

Mar 27, 2025

Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne - Benzinga

Mar 27, 2025

Mar 27, 2025

Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall - Benzinga

Mar 27, 2025

Mar 27, 2025

Pre-Market Momentum: Dermata Therapeutics (DRMA) Sees Sharp Gains - Stocks Telegraph

Mar 27, 2025

Mar 27, 2025

XYNGARI shows promise in Phase 3 acne trial By Investing.com - Investing.com South Africa

Mar 27, 2025

Mar 27, 2025

Dermata shares rise on positive acne treatment trial results By Investing.com - Investing.com South Africa

Mar 27, 2025

Mar 27, 2025

Dermata shares rise on positive acne treatment trial results - Investing.com

Mar 27, 2025

Mar 27, 2025

Dermata's XYNGARI(TM) Phase 3 Trial Topline Data Meets All Primary Endpoints - MarketScreener

Mar 27, 2025

Mar 27, 2025

XYNGARI shows promise in Phase 3 acne trial - Investing.com

Mar 27, 2025

Mar 27, 2025

First-Ever Weekly Acne Treatment XYNGARI Achieves Breakthrough in Phase 3 Trial - Stock Titan

Mar 27, 2025

Mar 26, 2025

Dermata Therapeutics Faces Nasdaq Delisting Notice By Investing.com - Investing.com India

Mar 26, 2025

Mar 25, 2025

Dermata Therapeutics Faces Nasdaq Delisting Notice - Investing.com

Mar 25, 2025

Mar 17, 2025

Dermata Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 17, 2025

Mar 17, 2025

Major Catalyst Alert: Dermata's Phase 3 Acne Treatment Results Coming in Weeks - StockTitan

Mar 17, 2025

Mar 12, 2025

Stocks Rally as US Consumer Prices Cool - The Globe and Mail

Mar 12, 2025

Mar 12, 2025

Acne Market on Track for Major Expansion by 2032, According to DelveInsight | Clinuvel Pharma, Novan, Dermata Therapeutics, ioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies - Barchart

Mar 12, 2025

Mar 12, 2025

Acne Market on Track for Major Expansion by 2032, According - openPR

Mar 12, 2025

Mar 11, 2025

Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne - openPR

Mar 11, 2025

Mar 11, 2025

Tesla Stock is OversoldIs Now the Time to Be Brave? - The Globe and Mail

Mar 11, 2025

Mar 10, 2025

Head-To-Head Analysis: Geron (NASDAQ:GERN) versus Dermata Therapeutics (NASDAQ:DRMA) - The AM Reporter

Mar 10, 2025

Mar 10, 2025

Geron (NASDAQ:GERN) versus Dermata Therapeutics (NASDAQ:DRMA) Head-To-Head Comparison - Defense World

Mar 10, 2025

Mar 04, 2025

Dermata Announces That Last Patient Completes Last Visit In Pivotal Xyngari Phase 3 Star-1 Clinical Trial For Acne - Marketscreener.com

Mar 04, 2025

Mar 04, 2025

Dermata Therapeutics announces last patient visit in Phase 3 acne trial - TipRanks

Mar 04, 2025

Mar 04, 2025

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne - PR Newswire

Mar 04, 2025

Mar 03, 2025

Acne Market Predicted to See Upsurge Through 2032, Highlights - openPR

Mar 03, 2025

Mar 03, 2025

Papulopustular Rosacea Clinical and Non-Clinical Studies, Key - openPR

Mar 03, 2025

Mar 03, 2025

APO accepts Dermata’s patent application for DMT410 program for hyperhidrosis - MSN

Mar 03, 2025

Feb 28, 2025

Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - Benzinga

Feb 28, 2025

Feb 25, 2025

DRMADermata Therapeutics Inc Latest Stock News & Market Updates - StockTitan

Feb 25, 2025

Feb 25, 2025

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis - ACCESS Newswire

Feb 25, 2025